Superworth

CONMED CNMD

Medical - Devices, Healthcare
$46.59
+5.19%
Market cap
$1.4B
PE
19.3×
10y median 52.9×
Forward PE
n/m
not a meaningful number
Price to sales
1.0×
EV/EBIT
19.8×
Revenue, 12 months
$1.4B
+2% on a year ago
Net margin
5.4%
Free cash flow yield
9.6%

CONMED trades at 19.3× trailing earnings, cheaper than 87% of the last ten years. Revenue was $1.4B over the last twelve months, up 2% on a year earlier with a 5% net margin.

Charts

Financials

Income statement for CNMD, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$327M+30%$312.3M+6%$332.1M+5%$316.7M+4%$345.9M+6%$321.3M+3%$342.3M+3%$337.9M+7%$373.2M+8%$317M−1%$343.5M+0%$335.6M−1%
Cost of revenue$144.9M+22%$140.3M+0%$148.4M+1%$137.7M+1%$147.6M+2%$143.5M+2%$154M+4%$171.8M+25%$154.9M+5%$133.6M−7%$146M−5%$146.4M−15%
Gross profit$182.2M+38%$172M+11%$183.7M+8%$179M+7%$198.3M+9%$177.8M+3%$188.3M+3%$166.1M−7%$218.3M+10%$183.4M+3%$197.5M+5%$189.1M+14%
R&D$14M+15%$13.6M+8%$14.1M+4%$13.6M+9%$13.2M−6%$12.9M−5%$14.1M+0%$13.9M+3%$14.9M+13%$16.3M+26%$15.5M+10%$15.6M+12%
SG&A$118M−2%$123.4M−5%$122.5M−6%$99.7M−20%$132.7M+13%$148.8M+21%$136M+11%$140.3M+41%$166.8M+26%$141.7M−5%$145.6M+7%$136.4M−3%
$50.2M$35M+176%$47.1M+72%$65.7M+117%$52.5M+5%$16M−54%$38.2M−19%$11.9M−82%$36.6M−30%$25.4M+59%$36.4M−5%$37.1M+213%
Interest expense$9.5M+1%$9.6M−6%$9.6M−4%$9.3M−8%$8.9M−7%$8.3M−14%$7.8M−18%$7.6M−18%$7.4M−17%$7.1M−15%$7.9M+1%$11.1M+46%
Pre-tax income$40.7M$25.4M+940%$37.5M+115%$56.5M+178%$43.6M+7%$7.7M−70%$29.9M−20%$4.3M−92%$29.3M−33%$18.4M+139%$31.3M+5%$26M+509%
$7.6M$5.7M+814%$7.5M+104%$7.5M+68%$9.9M+30%$1.6M−71%$8.5M+13%$1.4M−81%$12.5M+27%$4.5M+177%$8.3M−3%$6.2M+339%
Net income$33.1M+24%$19.7M+984%$30M+118%$49M+209%$33.8M+2%$6M−69%$21.4M−29%$2.9M−94%$16.7M−50%$13.8M+129%$23.1M+8%$19.8M+592%
$1.05+21%$0.63+950%$0.96+123%$1.57+214%$1.08+3%$0.19−70%$0.69−28%$0.09−94%$0.54−50%$0.45+137%$0.77+12%$0.66+633%
31.5M+3%31.3M+0%31.1M−2%31.1M−2%31.2M−1%31.2M−0%31.1M−0%31.1M−0%31.2M+0%30.6M−2%30.1M−3%30.1M−3%

EPS, diluted: 6 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 14 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY11: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Medical - Devices nearest CONMED's size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
CNMDCONMED$1.4B19.3×52.9×1.0×+2%5.4%
TMDXTransMedics$2.3B17.4×55.5×3.5×+26%22.7%
ITGRInteger$4.3B42.5×33.6×2.4×−0%5.7%
LIVNLivaNova$4.4B23.7×71.7×3.0×+12%12.8%
ELMDElectromed$223.9M20.4×29.0×3.0×+15%15.3%
Peer median$3.3B22.0×44.6×3.0×+14%14.1%

More on CONMED

Each number over time

Where it ranks

Its groups

About

Industry
Medical - Devices
Sector
Healthcare

Valuation data, not investment advice. Prices as of .